Katherine Rielly-Gauvin
Known title: DirectorCIK: 0001791718
Associated companies
Transaction History
| LQDA | ▲ Buy | Option Exercise | 11,727 | $29K | 8/20/2026 | View on chart |
| LQDA | ▲ Buy | Option Exercise | 6,666 | $17K | 8/20/2026 | View on chart |
| LQDA | ▼ Sell | Open Market | 18,393 | $1.3M | 8/20/2026 | View on chart |
| LQDA | ▲ Buy | Option Exercise | 23,455 | $59K | 8/19/2026 | View on chart |
| LQDA | ▲ Buy | Option Exercise | 13,334 | $35K | 8/19/2026 | View on chart |
| LQDA | ▼ Sell | Open Market | 36,789 | $2.8M | 8/19/2026 | View on chart |
| LQDA | ▲ Buy | Grant | 5,882 | $0 | 6/16/2026 | View on chart |
| LQDA | ▲ Buy | Grant | 18,396 | $0 | 6/17/2025 | View on chart |
| LQDA | ▲ Buy | Grant | 20,359 | $0 | 6/20/2024 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 7, 2026
Liquidia shares fall on patent court loss and analyst downgrades
Liquidia stock is down sharply after a court ruling regarding YUTREPIA patent access, which analysts say clouds the drug's future. Wells Fargo downgraded the stock to Equal-Weight and lowered its price target to $30, while other analysts also cut their targets. The stock is currently trading near its 52-week low, reflecting significant market concern over the legal outcome.
Liquidia shares fall on patent court loss and analyst downgrades. Liquidia stock is down sharply after a court ruling regarding YUTREPIA patent access, which analysts say clouds the drug's future. Wells Fargo downgraded the stock to Equal-Weight and lowered its price target to $30, while other analysts also cut their targets. The stock is currently trading near its 52-week low, reflecting significant market concern over the legal outcome.